Check-Cap Stock Forecast, Price & News

Check-Cap (NASDAQ:CHEK) Frequently Asked Questions

Is Check-Cap a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Check-Cap stock.
View analyst ratings for Check-Cap or view top-rated stocks.

How has Check-Cap's stock price been impacted by COVID-19 (Coronavirus)?

Check-Cap's stock was trading at $1.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CHEK shares have decreased by 46.3% and is now trading at $0.7084.
View which stocks have been most impacted by COVID-19.

Are investors shorting Check-Cap?

Check-Cap saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,860,000 shares, an increase of 18.5% from the October 31st total of 5,790,000 shares. Based on an average daily trading volume, of 1,470,000 shares, the short-interest ratio is currently 4.7 days.
View Check-Cap's Short Interest.

When is Check-Cap's next earnings date?

Check-Cap is scheduled to release its next quarterly earnings announcement on Friday, March 18th 2022.
View our earnings forecast for Check-Cap.

How were Check-Cap's earnings last quarter?

Check-Cap Ltd. (NASDAQ:CHEK) issued its earnings results on Wednesday, November, 3rd. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01.
View Check-Cap's earnings history.

When did Check-Cap's stock split? How did Check-Cap's stock split work?

Check-Cap's stock reverse split on Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 3rd 2018. An investor that had 100 shares of Check-Cap stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for CHEK?

2 Wall Street analysts have issued 12 month target prices for Check-Cap's shares. Their forecasts range from $2.00 to $3.00. On average, they expect Check-Cap's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 252.9% from the stock's current price.
View analysts' price targets for Check-Cap or view top-rated stocks among Wall Street analysts.

Who are Check-Cap's key executives?

Check-Cap's management team includes the following people:

• Alex Ovadia, Chief Executive Officer
• Joshua Belkar, Vice President-Operations
• Mira Rosenzweig, Chief Financial Officer
• Yoav Kimchy, Chief Technology Officer
• Boaz Shpigelman, Vice President-Research & Development

Who are some of Check-Cap's key competitors?

Some companies that are related to Check-Cap include Koninklijke Philips (PHG), Hologic (HOLX), Butterfly Network (BFLY), Nano-X Imaging (NNOX) and HealthCor Catalio Acquisition (HCAQ).
View all of CHEK's competitors.

What other stocks do shareholders of Check-Cap own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Check-Cap investors own include Alibaba Group (BABA), Navios Maritime Partners (NMM), New Residential Investment (NRZ), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Acasti Pharma (ACST), Avinger (AVGR), Biocept (BIOC) and Purple Biotech (KTOV).

When did Check-Cap IPO?

(CHEK) raised $13 million in an initial public offering (IPO) on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager.

What is Check-Cap's stock symbol?

Check-Cap trades on the NASDAQ under the ticker symbol "CHEK."

Who are Check-Cap's major shareholders?

Check-Cap's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.49%), Goldman Sachs Group Inc. (0.19%), UBS Group AG (0.05%) and Two Sigma Securities LLC (0.05%).

Which major investors are selling Check-Cap stock?

CHEK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

Which major investors are buying Check-Cap stock?

CHEK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., UBS Group AG, and Two Sigma Securities LLC.

How do I buy shares of Check-Cap?

Shares of CHEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Check-Cap's stock price today?

One share of CHEK stock can currently be purchased for approximately $0.71.

How much money does Check-Cap make?

Check-Cap has a market capitalization of $68.29 million. The medical research company earns $-13.85 million in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Check-Cap have?

Check-Cap employs 65 workers across the globe.

What is Check-Cap's official website?

The official website for Check-Cap is www.check-cap.com.

Where are Check-Cap's headquarters?

Check-Cap is headquartered at 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000.

How can I contact Check-Cap?

Check-Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company can be reached via phone at 972546706451, via email at [email protected], or via fax at 972-4821-1267.